Exagen Inc
NASDAQ:XGN

Watchlist Manager
Exagen Inc Logo
Exagen Inc
NASDAQ:XGN
Watchlist
Price: 4.7 USD -3.89% Market Closed
Market Cap: $106.5m

Operating Margin

-19.6%
Current
Improving
by 25.3%
vs 3-y average of -44.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-19.6%
=
Operating Income
$-12.5m
/
Revenue
$63.6m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-19.6%
=
Operating Income
$-12.5m
/
Revenue
$63.6m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Exagen Inc
NASDAQ:XGN
110.1m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.4B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
169B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.1B USD
Loading...
AU
CSL Ltd
ASX:CSL
87B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.8B USD
Loading...

Market Distribution

Lower than 76% of companies in the United States of America
Percentile
24rd
Based on 14 112 companies
24rd percentile
-19.6%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Exagen Inc
Glance View

Market Cap
106.5m USD
Industry
Biotechnology

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. The company is headquartered in Vista, California and currently employs 219 full-time employees. The company went IPO on 2019-09-19. The firm offers physicians testing for patients and healthcare providers in diagnosis, prognosis, and monitoring of autoimmune conditions. The firm develops and commercialize testing products under the brand name AVISE. Its products include AVISE CTD, AVISE Lupus, AVISE APS, AVISE Vasculitis AAV, AVISE SLE Prognostic, AVISE Anti-CarP, AVISE PC4d, AVISE SLE Monitor and AVISE MTX. The firm's lead testing product AVISE enables diagnosis for patients with symptoms of connective tissue diseases (CTD) and Systemic lupus erythematosus (SLE). The Company’s AVISE brand allows for the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis (RA). The Company’s product portfolio integrates proprietary CB-CAPs technology, which is a stable and reliable method for differentially diagnosing systemic lupus erythematosus.

XGN Intrinsic Value
2.58 USD
Overvaluation 45%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-19.6%
=
Operating Income
$-12.5m
/
Revenue
$63.6m
What is Exagen Inc's current Operating Margin?

The current Operating Margin for Exagen Inc is -19.6%, which is above its 3-year median of -44.9%.

How has Operating Margin changed over time?

Over the last 3 years, Exagen Inc’s Operating Margin has increased from -83.2% to -19.6%. During this period, it reached a low of -95% on Mar 31, 2023 and a high of -19.6% on Sep 30, 2025.

Back to Top